Literature DB >> 11484688

Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

J H Newman1, L Wheeler, K B Lane, E Loyd, R Gaddipati, J A Phillips, J E Loyd.   

Abstract

BACKGROUND: Most patients with primary pulmonary hypertension are thought to have sporadic, not inherited, disease. Because clinical disease develops in only 10 to 20 percent of persons carrying the gene for familial primary pulmonary hypertension, we hypothesized that many patients with apparently sporadic primary pulmonary hypertension may actually have familial primary pulmonary hypertension.
METHODS: In a study conducted over 20 years, we developed a registry of 67 families affected by familial primary pulmonary hypertension. Through patient referrals, extensive family histories, and correlation of family pedigrees, we discovered shared ancestry among five subfamilies. We established the diagnosis of primary pulmonary hypertension by direct evaluation of patients and review of autopsy material and medical records. We assessed some family members for mutations in the gene encoding bone morphogenetic protein receptor II (BMPR2), which has recently been found to cause familial primary pulmonary hypertension.
RESULTS: We linked five separately identified subfamilies that included 394 known members spanning seven generations, which were traced back to a founding couple in the mid-1800s. Familial primary pulmonary hypertension has been diagnosed in 18 family members, 12 of whom were first thought to have sporadic disease. The conditions of 7 of the 18 were initially misdiagnosed as other cardiopulmonary diseases. Six members affected with familial primary pulmonary hypertension and 6 of 10 at risk for carriage have been undergone genotype analysis, and they have the same mutation in BMPR2, a transversion of thymine to guanine at position 354 in exon 3.
CONCLUSIONS: Many cases of apparently sporadic primary pulmonary hypertension may be familial. Failure to detect familial primary pulmonary hypertension results from incomplete expression within families, skipped generations, and incomplete family pedigrees. The recent discovery of mutations in BMPR2 should make it possible to identify those with susceptibility to disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11484688     DOI: 10.1056/NEJM200108023450502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  106 in total

Review 1.  Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension.

Authors:  M Rabinovitch
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  Treatment of pulmonary hypertension.

Authors:  Andrew J Peacock
Journal:  BMJ       Date:  2003-04-19

Review 3.  [Consensus recommendations of the Pulmonary Arterial Hypertension Study Group of the Austrian Society of Lung Diseases and Tuberculosis].

Authors:  Rolf Ziesche
Journal:  Wien Klin Wochenschr       Date:  2003-05-30       Impact factor: 1.704

Review 4.  Pathobiology of pulmonary arterial hypertension and right ventricular failure.

Authors:  Norbert F Voelkel; Jose Gomez-Arroyo; Antonio Abbate; Harm J Bogaard; Mark R Nicolls
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

Review 5.  The role of mitochondria in pulmonary vascular remodeling.

Authors:  Peter Dromparis; Gopinath Sutendra; Evangelos D Michelakis
Journal:  J Mol Med (Berl)       Date:  2010-08-24       Impact factor: 4.599

Review 6.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

7.  Kinase activity profiling of gram-negative pneumonia.

Authors:  Arie J Hoogendijk; Sander H Diks; Maikel P Peppelenbosch; Tom Van Der Poll; Catharina W Wieland
Journal:  Mol Med       Date:  2011-03-15       Impact factor: 6.354

Review 8.  [Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment].

Authors:  K Ahmadi-Simab; W L Gross
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 9.  Severe paediatric pulmonary hypertension: new management strategies.

Authors:  A Rashid; D Ivy
Journal:  Arch Dis Child       Date:  2005-01       Impact factor: 3.791

10.  Visceral manifestations in hereditary haemorrhagic telangiectasia type 2.

Authors:  S A Abdalla; U W Geisthoff; D Bonneau; H Plauchu; J McDonald; S Kennedy; M E Faughnan; M Letarte
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.